Participated · Seed · Aug 2025

Recornea is a clinical-stage Italian medtech company developing the GROSSO® Reshaper, a nitinol corneal implant designed to restore vision in patients with keratoconus. The GROSSO® Reshaper uses a predefined physiological curvature to remodel the cornea with predictable visual results and is built on a nitinol platform that the company says can be applied to other ocular conditions. Recornea completed preclinical work including biocompatibility testing and a six-month rabbit study showing the implant was well tolerated. A First-in-Human (FIH) study on 12 patients is underway at the Instituto de Microcirugía Ocular (IMO) in Barcelona, with a second FIH planned at Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome; the first implanted patient showed excellent safety and promising early efficacy. The company is also exploring a nitinol-based filtering device for glaucoma as a second product in its pipeline. Funds recently raised will be used to complete the ongoing FIH studies and advance the pipeline toward larger clinical trials and commercialization. Recornea has developed GROSSO, the first nitinol corneal implant designed to help patients with advanced keratoconus recover vision. The implant can be inserted via a conservative-additive refractive surgery that does not require removal of corneal tissue. Recornea says its technology restores the physiological curvature of the cornea, a significant improvement over traditional intracorneal ring segments. Current standards cited in the article include corneal cross-linking for early disease and ICRS for advanced cases. The company aims to improve quality of life for keratoconus patients and integrate its solution into routine clinical practice. Recornea announced a €150,000 financing led by Scientifica Venture Capital to support these efforts.

Participated · Seed · Jun 2023

Aliform develops an innovative surgical tool that enables physicians to treat skin connective tissue defects in a minimally invasive manner. The company's technology aims to help skin surgeons treat a range of connective tissue problems more safely and cost‑effectively while minimizing functional and aesthetic damage. Aliform said it will use the Seed funding to get its first product to market, expand the team, and advance toward clinical stage work. The company announced a $1.7 million Seed round on June 15, 2023 in Dallas, Texas. Brightlands Venture Partners led the round and invested $1.5 million, with participation from a group of business angel investors and US accelerator Health Wildcatters. Aliform positions its tools as easy for surgeons to use and as a way to improve patient outcomes and reduce costs for clinics.

Participated · Seed · Mar 2015

Orb Health is a Phoenix, AZ-based collaborative care technology platform led by CEO and co-founder Paul Oran. The company offers a cloud-based platform that optimizes clinical workflow by integrating EMRs, real-time data from wearable fitness and healthcare trackers, proprietary patient engagement tools, and deep healthcare information. Its tools are designed to help care professionals engage with patients and deliver a higher standard of collaborative care. The platform targets physician-owned practices and large health systems. Orb Health also aims to help providers maximize chronic care management revenue opportunities. The company plans to use new capital to expand and accelerate growth of its intelligent collaborative care platform. Orb Health offers a health data exchange platform that lets patients sync wearable-device data and access and simplify lab test results for clearer patient understanding. The service integrates data from 120 lab networks (including Quest Diagnostics), 30 EMR platforms, and more than 150 wearable devices and apps, and it shows patients how their health has changed over time. Orb Health works with Validic for device integrations and presents lab results to physicians using colorful charts and graphics to facilitate review with patients. The company aims to make both patient-facing and clinician-facing views more actionable by consolidating disparate data sources. Orb Health participated in Dallas-based accelerator Health Wildcatters' second class, which began in August 2014. The company has announced a $650,000 fundraise to support its platform and operations.